UPenn researchers believe that their lateral flow assay has the potential to be the first point-of-care test that can detect fentanyl and its metabolite, norfentanyl, at clinically relevant cutoffs.
Since FDA's actions, the company has implemented a program in which customers must sign a certification letter saying they are using its products as intended.
The Oakland, California-based company will use the funding to speed the manufacturing and commercialization of its dual alcohol and marijuana breathalyzer.
